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Caring for Cardiovascular Disease in Patients with SLE
Diondra M. Penland BSN, RN
Otterbein University, Westerville, Ohio
Introduction
In the U.S., approximately 5-20
people per 100,000 are affected with the
complex autoimmune disorder called
Systemic Lupus Erythematosus (SLE).
SLE affects predominately more females
than males (9:1female to male), with a
higher incidence in African American
women. (Barbehaiya, Costenbader,
Parks, & Santos, 2017). SLE is a
debilitating condition that has
multisystem involvement which affects
the skin, renal, musculoskeletal, and
cardiac systems. “SLE is caused by
interactions between susceptible genes
and environmental factors, which can
include ultraviolet light, infections, and
viruses, resulting in an irreversible loss
of immunologic self-tolerance”
(Garyfallos, Goulielmos, Niewold, &
...Zervou, 2018, p. 59).

Pathophysiology on Atherogenesis in SLE
Signs & Symptoms
•Fatigue

Diagnosis

•Butterfly-shaped rash on face

Lupus is difficult to diagnose
because its signs and symptoms mimic
other conditions. This is a condition that
progresses slowly over years, and it has
episodic periods of exacerbation and
remission. (Paz MD, 2017). You have to
have at least four of the eleven clinical
findings to be diagnosed with SLE:

•Photosensitivity

1.) Malar Rash

•Chest pain when taking a

2.) Discoid Rash

•Fever
•Joint pain, stiffness and
swelling

The exact mechanisms that lead to increased risk for heart failure in SLE are not known,
however data shows that aberrant host-immune response and chronic inflammation lead to
accelerated atherosclerosis (Al-Kindi, Dhakal, Kim, & Oliveira, 2018). “In addition, SLE has
direct cardiac, vascular, and other systemic manifestations that lead to increased risk of
cardiovascular disease and heart failure” (p.188).
Endothelial Dysfunction
Endothelial dysfunction is one of the earliest signs of atherosclerosis, resulting in increased
expression of adhesion molecules and impaired vasodilation. An imbalance between circulating
apoptotic endothelial cells (ECs) indicate vascular damage and contribute to endothelial
dysfunction. Also patients with SLE have increased concentrations of reactive oxygen species
and decreased antioxidant defense mechanisms which provide a conducive environment for
oxidation of lipoproteins and atherosclerosis (Bortoluzzi, et al., 2018, pp. 2-3).

4.) Photosensitiviety
5.) Arthritis

•Weight loss

6.) Lung or Heart Inflammation

Just a couple of years back my
mother had a Non ST Elevated
Myocardial Infarction which lead to her
diagnosis of SLE. Our family was not
knowledgeable regarding this condition
because no one in our family has SLE.
Now every chance I get I try to learn as
much about SLE to help better care for
my mother and myself. Through research
I’ve learned that I have a few of the risk
factors that would put me at a higher
incidence of developing the condition.
Firstly, I am an African American
woman of childbearing age which
increases my prevalence of developing
the condition. This is an eye opener for
because in SLE young women have a 50
times higher risk for myocardial
infarction compared to healthy women of
similar age distribution (Giannelou &
Mavragani, 2017). Secondly, I have a
higher incidence due to the fact that SLE
is hereditary and my mom has the
condition. It is for these reasons that I
chose to research SLE.

•Mouth sores

SLE Manifestations increase the risk
factors for Heart Failure

Active SLE is no longer the major
cause of death in the condition. Now
mortality arises from conditions such as
cardiovascular disease or renal failure
complications. Obesity and hypertension
are some of the known contributors of
atherosclerosis. It is recommended that
SLE patients with these conditions do
things to try to reverse or control the
condition. Bichele and Petri recommend
a 500 calorie deficit from their diet as a
well as two and a half hours of moderate
intensity aerobic exercise weekly to
decrease obesity (2014). Also,
“guidelines recommend a target blood
pressure of less than 130/80 mmHg"
(Bichile & Petri, 2014) to manage
hypertension.

Myocardial Dysfunction: Left Ventricular
Systolic Dysfunction or Diastolic
Dysfunction
Left Ventricular Hypertrophy: Secondary
to arterial HTN and correlation between
SLE duration and left ventricular mass

Conduction System Disease: SLE may
manifest as arrhythmias such as atrial
fibrillation and complete heart block

•Hair loss

Endocarditis: SLE predisposes people to
infective and non-infective endocarditis

7.) Renal Problems
Cardiovascular disease is a leading
cause of mortality in the world, and
atherosclerosis is a hallmark in the
disease. People with SLE have a 6-fold
higher risk of developing atherosclerotic
lesions that cause cardiovascular disease
(Leng, Li, & ...Ye, 2015). “Increasing
evidence shows that the cardiovascular
morbidity and mortality are significantly
higher in SLE than in the general
population” (p.23).

Nursing
Implications

Valvular Disease: is common in SLE
however over heart failure due to valvular
involvement is rare

3.) Mouth Ulcers

deep breath

Significance of
Pathophysiology

8.) Neurologic Problems

•Raynaud’s phenomenom

9.) Hematologic Problems

•Swollen lymph nodes

10.) Immunologic Problems

Myocarditis: can lead to conduction
problems, dilated cardiomyopathy, and
heart failure

11.) Positive Antinuclear Antibodies

•Headaches

Pericardititis: manifests as pleuritic
substernal pain and the most frequent
cause of symptomatic cardiac disease in
SLE

(Paz MD, 2017)

•Memory loss
•Seizures
(Paz MD, 2017)
Monocytes and T-Cell Recruitment and Activation
Monocytes can migrate into the intima and differentiate into macrophages, which leads to a
further transformation into foam cells that secrete proinflammatory cytokines (Bortoluzzi, et al.,
2018).
T-cells, predominately CD4 cells, have an increased affinity to infiltrate newly formed
atherosclerotic plaques (Bortoluzzi, et al., 2018).
Toll-Like Receptors
Toll-like receptors (TLRs) are a class of pattern recognition receptors expressed on multiple
cells involved in innate immunity. In SLE, people have a dysregulated activation of TLRs,
resulting in upregulated production of autoantibodies and cytokines (Bortoluzzi, et al., 2018).
This leads to the recruitment of activated inflammatory cells, self-perpetuating the process of
inflammation and plaque formation (p.3).
Cytokines
Cytokines such as interferons alpha and gamma (INF) are involved in atherosclerosis and SLE.
“IFN alpha serves as a proatherogenic mediator through repression of endothelial nitric oxide
synthase-dependent pathways promoting the development of endothelial dysfunction and
cardiovascular disease in SLE” (Bortoluzzi, et al., 2018, p. 3).
IFN gamma participates in atherogenesis by stimulating ECs and macrophage activation,
proinflammatory mediator production, adhesion-molecule expression, and by inhibiting smooth
muscle cell proliferation and collagen production (Bortoluzzi, et al., 2018, p. 3).
Other cytokines participate in the initiation and perpetuation of the atherosclerotic process by
stimulating the activation of macrophages, inducing the secretion of matrix metalloproteinases,
upregulating the expression of adhesion molecules on the ECs, increasing the concentration of
chemotactic messengers, and affecting the proliferation of smooth muscle cells (Bortoluzzi, et
al., 2018, p. 3).

Anaphospholipid Syndrome: predisposes
people to valvular disease, arterial and
venous thrombosis, and pulmonary
hypertension

(Al-Kindi, Dhakal, Kim, & Oliveira,
2018)

Conclusions
Systemic Lupus Erythematosus is a
complex autoimmune inflammatory
condition that increases the risk for
atherosclerosis. Cardiovascular disease is the
leading cause of death in the U.S. and
atherosclerosis is the most common risk
factor. SLE is non curable however advances
in research has allowed people with the
condition to live longer. More research is
needed on the complex pathophysiology of
the condition to better understand the disease
process.

Advances in disease management
have improved survival of SLE patients
and shifted the focus to other outcome
parameters such as measuring quality of
life (Carnarius, Chehab, & Schneider,
2014). Caregivers should be sensitive to
the mental and physical attributes that
come along with SLE. Fatigue,
depression, and pain are common
symptoms in SLE that lead to a
decreased quality of life.
Depression and anxiety in SLE increases
the incidence of co-morbidities such as
cardiovascular disease (Carnarius,
Chehab, & Schneider, 2014).
The pain and discomfort of SLE can be
physically and mentally debilitating.
Encourage SLE patients to maintain
activity when the symptoms are mild or
in remission (Carnarius, Chehab, &
Schneider, 2014).
Caregivers should be educated on the
medications to help treat SLE, and be
ready to advocate on their behalf.
Hydroxychloroquine is an antimalarial
with known benefits in treating SLE,
however the percentage of people taking
the medication remains low (Chalumeau,
Dunogue, Guern, Imber, & Morel,
2014). Hydroxychloroquine helps
“reduce the high cardiovascular risk of
SLE patients” (p. 168).
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